Dr. Anand invitation to speak at 11Th International Congress on Autoimmunity at Lisbon, Portugal.
Dear Anand S,
Greetings from Clinical Research and Trials (CRT) !
This is a special Request regarding manuscript contribution to our Journal. We will be glad if you can submit your manuscript along with cover letter at email@example.com
We would like to inform you regarding our Annual Membership Program. Keeping in view your tremendous contribution to the scientific field, we wish to offer you free membership.
Kindly let us know your opinion in this regard. So, that we will send you more details regarding individual membership and other benefits.
Awaiting for your positive response.
Have a great day
Office Gold, building 3 Chiswick Park
Greater London, W4 5YA
Sanford Health is conducting the first clinical trial approved by the FDA to treat injured shoulders using patients’ adipose stem cells.
“A number of studies have demonstrated that fat-derived stem cells have great healing potential by boosting the immune system and helping the natural healing process,” Jason Hurd, MD, a principal investigator of the study and orthopedic surgeon at Sanford Orthopedics & Sports Medicine in Sioux Falls, South Dakota, told Orthopedics Today. “Also, isolation of fat tissue is less invasive than isolation of other pools of stem cells, such as those found in the bone marrow, which might include a more complicated surgical procedure.”
Hurd and Mark Lundeen, MD, the other lead investigator of the study, began the trial in December to determine whether adipose stem cells, extracted from a patient’s abdominal fat, could repair partial thickness tears in the rotator cuff, according to a press release from Sanford Health. Investigators hypothesize that injecting the stem cells into the injured area could activate the patient’s body’s natural healing process, accelerate healing and regenerate tissue.
“Sanford Health physicians and scientists are the first in the country to work with the FDA on a trial using adipose stem cells in rotator cuff tears, which are common,” Kelby Krabbenhoft, president and chief executive officer of Sanford Health, said in the release. “We have been monitoring the potential of these types of stem cells for some time. In Europe, adipose stem cells have been used as a therapy option for damaged tissues and are approved to carry the CE mark, which signifies that a product has been assessed by and meets certain safety, health and environmental protection requirements in the European Union.” ‒ by Monica Jaramillo
Source : https://goo.gl/VLSG84
It started with a hand tremor that was more pronounced when typing. At first, it just interfered with hobbies. But it got progressively worse. Soon handwriting was illegible. The simple act of walking became difficult. Memory problems and an urgency to urinate finally send the patient to the doctor, for the cruel diagnosis: Parkinson disease, a condition resulting from cell degeneration in the brain.
There are other disorders like it, Alzheimer for example, that share an important trait — they arise when the body’s aging cells stop doing what they are supposed to do.
For many of these conditions, there are no cures, just treatments designed to slow the progression, where possible. But we may soon be looking at new treatment options developed through mitochondrial genetics and the study of aging.
The degeneration of aging cells is related to abnormalities in power plant organelles called mitochondria. In normal cell function, these mitochondria deteriorate over time and are eventually ejected from the cell.
Over the past few decades, researchers have discovered evidence that mitochondria become dysfunctional because of mutations in their DNA. (Mitochondrial DNA, or mtDNA, is separate from the DNA comprising the chromosomes of a cell’s nucleus.) The dysfunction, in turn, is connected to cellular aging and the onset of degenerative diseases. There are two new developments in this area of research.
The first involves the realization that while certain mtDNA mutations contribute to the disruption of mitochondrial function, there are mutations in other mitochondrial genes that prevent the cell from removing the dysfunctional mitochondria. Essentially, the cell loses the ability to perform its own quality control.
“We know that increased rates of mtDNA mutation cause premature aging,” said Bruce Hay, Professor of biology and biological engineering at the California Institute of Technology. “This, coupled with the fact that mutant mtDNA accumulates in key tissues such as neurons and muscle that lose function as we age, suggests that if we could reduce the amount of mutant mtDNA, we could slow or reverse important aspects of aging.”
This brings us to the second major development relevant to mitochondria in disease — that genetic technology is now at a point where the targeted removal of the problem mitochondrial genes can become the basis for clinical intervention. This is the implication of research that Hay and colleagues both at Caltech and the University of California at Los Angeles have described in a paper published recently in the prestigious journal Nature Communications.
Fixing body tissues by knocking out genes that prevent bad mitochondrial from being ousted in a timely fashion might sound like science fiction, but that’s where things are going and it’s part of a growing trend of what’s being described as mitochondrial medicine.
With degenerative diseases, the standard treatment involves the replacement of the physiologic function of the diseased tissue. In Parkinson disease, this often means replacing a neurotransmitter called dopamine in a part of the brain where it’s lacking, due to degeneration of dopamine-making cells. While this works well in the initial stages of the disease, it gradually becomes less effective.
There are two new strategies. One is to regenerate the failing tissue using stem cells. The other is gene therapy in which the patients’ own brain cells are given the ability to make something they don’t usually make. For instance, the part of the brain that usually receives dopamine is given the ability to make its own dopamine.
Neurosurgeons are actually quite good at injecting agents into specific regions of the brain with extreme precision. This is why gene therapy and stem cell therapy are showing promise. But this also means there’s a capability to deliver agents that could affect mitochondria. It means that it should be possible in the near future to manage degenerative diseases with a third advance treatment prong: restoring the cell’s ability to expel failing mitochondria.
Source : https://goo.gl/JdfS9M
We are still in the early stages [of stem cell treatment]. In 2014, Dr. Masayo Takahashi and her colleagues at the Riken Center for Developmental Biology had great success using iPS cells to treat macular degeneration.
In some ways, yes, [the promise of stem cells] is overstated. For example, target diseases for cell therapy are limited. There are about 10: Parkinson’s, retinal and corneal diseases, heart and liver failure, diabetes and only a few more — spinal cord injury, joint disorders and some blood disorders…The number of human diseases is enormous.
I think the science has moved too far ahead of talk of ethical issues. When we succeeded in making iPS cells, we thought, wow, we can now overcome ethical issues of using embryos to make stem cell lines.
But soon after, we realized we are making new ethical issues. We can make a human kidney or human pancreas in pigs if human iPS cells are injected into the embryo. But how much can we do those things?
It is very controversial. These treatments may help thousands of people. So getting an ethical consensus is extremely important.
Source : https://goo.gl/1tIykZ
Dear Doctor Srivastava,
Hope you are doing well.
Integrative Molecular Medicine (IMM) welcomes you to contribute any type of articles for Volume 4 Issue 1. Kindly submit your article by January 20th, 2017. Your scientific contribution would help in enhancing the rating of this journal.
Our journal is indexed in the following services mentioned below:
Google Scholar, German Cancer Research Center, EZB Electronic Journals Library, World cat, Zeitschriftendatenbank (ZDB), Citefactor, Road Directory, SciCurve, AS-FHJ, RefSeek. We are applied for Indexing in EBSCO, EMBASE, and CAS. We are sure that your article will enhance the impact of our journal.
Awaiting your response.
Feel free to contact us for further queries.
Managing Editor for Editor-in-chief (Koji Wakame)
Integrative Molecular Medicine (IMM) (2056-6360)